
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Bluejay Diagnostics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

Ross. D. Carmel, Esq.
1185 Avenue of the Americas, 26th Floor
New York, NY, 10036
(212) 930-9700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

Name of reporting person

1

Braeden Lichti

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 PF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 CANADA (FEDERAL LEVEL)

Sole Voting Power

7

0.00

Number of Shares Beneficially Owned by

Shared Voting Power

8

0.00

Each Reporting Person

Sole Dispositive Power

9

0.00

With: Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11 0.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 0.00 %

Type of Reporting Person (See Instructions)

14 IN

Comment for Type of Reporting Person: On June 2, 2026, Mr. Lichti sold all of his previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person.

SCHEDULE 13D

CUSIP No.

Name of reporting person

1 Northstrive Fund II LP

Check the appropriate box if a member of a Group (See Instructions)

2 (a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

6 Citizenship or place of organization

DELAWARE

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially 8

0.00

Owned by

Sole Dispositive Power

Each

Reporting 9

0.00

Person

With:

Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11

0.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12



Percent of class represented by amount in Row (11)

13

0.00 %

Type of Reporting Person (See Instructions)

14

PN

Comment for Type of Reporting Person: Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP ("Northstrive Fund"). On June 2, 2026, Northstrive Fund sold all of its previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, par value \$0.0001 per share

Name of Issuer:

(b)

Bluejay Diagnostics, Inc.

Address of Issuer's Principal Executive Offices:

(c)

360 Massachusetts Avenue, Suite 203, Acton, MASSACHUSETTS , 01720.

Item 1 Comment: Mr. Braeden Lichti and Northstrive Fund previously filed a Schedule 13D on March 11, 2026. This Amendment No. 1 relates to the Common Stock of the Issuer and amends the Schedule 13G. The principal executive offices of the Issuer are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

Item 2. Identity and Background

(a)

Mr. Lichti serves as the Manager of Northstrive Fund. As of the date of this Amendment, neither Reporting Person beneficially owns any shares of the Issuer's Common Stock, as reflected on the cover pages and in Item 5.

(b)

The address of each of the Reporting Persons is 120 Newport Center Drive, Newport Beach, CA 92660.

(c)

Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company.

(d)

Mr. Lichti has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).

(e)

None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

- (f) Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada.
- Item 3. Source and Amount of Funds or Other Consideration
Not applicable. This Amendment reports only the disposition of all shares previously reported on the Schedule 13D and no additional securities were acquired since the Schedule 13D filed with the SEC on March 11, 2026. As of the date of this Amendment, the Reporting Persons beneficially own 0 shares of the Issuer's Common Stock.
- Item 4. Purpose of Transaction
Since the filing of the Reporting Persons' Schedule 13D with the SEC on March 11, 2026, the Reporting Persons have disposed of all shares of common stock of the Issuer. As of June 2, 2026, the Reporting Persons no longer beneficially own any shares of the Issuer's Common Stock.
- Item 5. Interest in Securities of the Issuer
- (a) As of the date of this Amendment, the Reporting Person do not beneficially own any shares of the Issuer's common stock. The information set forth on the cover pages of this Amendment is incorporated herein by reference.
Sole power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Shared power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares
- (b) Sole power to dispose or to direct the disposition of: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Shared power to dispose or to direct the disposition: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares
- (c) The information set forth in Item 3 above is incorporated herein by reference.
- (d) Not applicable.
- (e) As of June 2, 2026, the Reporting Persons ceased to be beneficial owners of more than five percent of the Issuer's outstanding Common Stock. This Amendment is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.
- Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
The information in Items 3 and 4 is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Braeden Lichti

Signature: /s/ Braeden Lichti

Name/Title: Braeden Lichti

Date: 06/02/2026

Northstrive Fund II LP

Signature: /s/ Braeden Lichti

Name/Title: Braeden Lichti/Manager

Date: 06/02/2026